These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12240794)

  • 1. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study.
    Auiler JF; Liu K; Lynch JM; Gelotte CK
    Curr Med Res Opin; 2002; 18(5):311-6. PubMed ID: 12240794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study.
    González MA; Polli JE; Morgan JA
    Curr Med Res Opin; 2002; 18(7):vii-x. PubMed ID: 12487510
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release.
    Ermer JC; Shojaei A; Pennick M; Anderson CS; Silverberg A; Youcha SH
    Curr Med Res Opin; 2007 May; 23(5):1067-75. PubMed ID: 17519073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.
    Ermer JC; Adeyi BA; Pucci ML
    CNS Drugs; 2010 Dec; 24(12):1009-25. PubMed ID: 21090837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate bioavailability from two extended-release formulations.
    González MA; Pentikis HS; Anderl N; Benedict MF; DeCory HH; Dirksen SJ; Hatch SJ
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):175-84. PubMed ID: 11996212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Gnagy EM; Chronis AM; Burrows-MacLean L; Fabiano GA; Onyango AN; Meichenbaum DL; Williams A; Aronoff HR; Steiner RL
    Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration.
    Tulloch SJ; Zhang Y; McLean A; Wolf KN
    Pharmacotherapy; 2002 Nov; 22(11):1405-15. PubMed ID: 12432966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to comments by Gonzalez et al. on the CONCERTA, Adderall XR Food Evaluation (CAFE) study.
    Auiler JF; Lynch JM; Gelotte CK
    Curr Med Res Opin; 2003; 19(1):64-5. PubMed ID: 12661783
    [No Abstract]   [Full Text] [Related]  

  • 14. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.
    Liu T; Gobburu JVS; Po MD; McLean A; DeSousa NJ; Sallee FR; Incledon B
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):181-191. PubMed ID: 30810347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
    Weisler RH; Stark JG; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
    Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
    Katzman MA; Sternat T
    CNS Drugs; 2014 Nov; 28(11):1005-33. PubMed ID: 25120227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.